Annual FCF
-$23.91 M
+$37.69 M+61.18%
31 December 2023
Summary:
Seelos Therapeutics annual free cash flow is currently -$23.91 million, with the most recent change of +$37.69 million (+61.18%) on 31 December 2023. During the last 3 years, it has fallen by -$3.00 million (-14.34%). SEEL annual FCF is now -772.26% below its all-time high of -$2.74 million, reached on 31 December 2008.SEEL Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$972.00 K
+$3.67 M+79.06%
30 June 2024
Summary:
Seelos Therapeutics quarterly free cash flow is currently -$972.00 thousand, with the most recent change of +$3.67 million (+79.06%) on 30 June 2024. Over the past year, it has increased by +$4.78 million (+83.09%). SEEL quarterly FCF is now -136.21% below its all-time high of $2.68 million, reached on 30 September 2018.SEEL Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$13.27 M
+$4.93 M+27.09%
30 June 2024
Summary:
Seelos Therapeutics TTM free cash flow is currently -$13.27 million, with the most recent change of +$4.93 million (+27.09%) on 30 June 2024. Over the past year, it has increased by +$21.82 million (+62.17%). SEEL TTM FCF is now -1787.52% below its all-time high of $786.60 thousand, reached on 30 September 2009.SEEL TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SEEL Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +61.2% | +83.1% | +62.2% |
| 3 y3 years | -14.3% | +90.8% | +60.9% |
| 5 y5 years | -194.2% | +66.6% | +37.2% |
SEEL Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.3% | +61.2% | at high | +95.2% | at high | +80.1% |
| 5 y | 5 years | -194.2% | +61.2% | at high | +95.2% | at high | +80.1% |
| alltime | all time | -772.3% | +61.2% | -136.2% | +95.2% | -1787.5% | +80.1% |
Seelos Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$972.00 K(-79.1%) | -$13.27 M(-27.1%) |
| Mar 2024 | - | -$4.64 M(+142.9%) | -$18.21 M(-23.9%) |
| Dec 2023 | -$23.91 M(-61.2%) | -$1.91 M(-66.8%) | -$23.91 M(-31.9%) |
| Sept 2023 | - | -$5.75 M(-2.6%) | -$35.09 M(-13.2%) |
| June 2023 | - | -$5.90 M(-42.9%) | -$40.42 M(-26.4%) |
| Mar 2023 | - | -$10.35 M(-20.9%) | -$54.91 M(-10.9%) |
| Dec 2022 | -$61.60 M(+25.7%) | -$13.09 M(+18.2%) | -$61.60 M(-7.9%) |
| Sept 2022 | - | -$11.07 M(-45.7%) | -$66.85 M(+0.9%) |
| June 2022 | - | -$20.39 M(+19.7%) | -$66.29 M(+21.0%) |
| Mar 2022 | - | -$17.05 M(-7.1%) | -$54.79 M(+11.8%) |
| Dec 2021 | -$48.99 M(+134.3%) | -$18.34 M(+74.5%) | -$48.99 M(+44.2%) |
| Sept 2021 | - | -$10.51 M(+18.2%) | -$33.98 M(+22.9%) |
| June 2021 | - | -$8.89 M(-21.0%) | -$27.66 M(+7.4%) |
| Mar 2021 | - | -$11.25 M(+238.0%) | -$25.74 M(+23.1%) |
| Dec 2020 | -$20.91 M(+8.3%) | -$3.33 M(-20.4%) | -$20.91 M(-7.9%) |
| Sept 2020 | - | -$4.18 M(-40.1%) | -$22.70 M(+5.9%) |
| June 2020 | - | -$6.98 M(+8.7%) | -$21.43 M(+20.5%) |
| Mar 2020 | - | -$6.42 M(+25.5%) | -$17.79 M(-7.9%) |
| Dec 2019 | -$19.30 M(+137.5%) | -$5.12 M(+75.9%) | -$19.30 M(-8.6%) |
| Sept 2019 | - | -$2.91 M(-12.8%) | -$21.13 M(+36.0%) |
| June 2019 | - | -$3.34 M(-58.0%) | -$15.54 M(+9.9%) |
| Mar 2019 | - | -$7.94 M(+14.3%) | -$14.14 M(+74.0%) |
| Dec 2018 | -$8.13 M(-22.3%) | -$6.95 M(-358.8%) | -$8.13 M(+122.3%) |
| Sept 2018 | - | $2.68 M(-238.4%) | -$3.66 M(-61.0%) |
| June 2018 | - | -$1.94 M(+0.6%) | -$9.37 M(-3.4%) |
| Mar 2018 | - | -$1.93 M(-22.0%) | -$9.70 M(-7.3%) |
| Dec 2017 | -$10.47 M(-20.0%) | -$2.47 M(-18.3%) | -$10.47 M(-2.2%) |
| Sept 2017 | - | -$3.03 M(+33.5%) | -$10.70 M(+25.4%) |
| June 2017 | - | -$2.27 M(-15.8%) | -$8.53 M(-10.3%) |
| Mar 2017 | - | -$2.70 M(-0.3%) | -$9.51 M(-27.3%) |
| Dec 2016 | -$13.09 M(-43.1%) | -$2.71 M(+214.2%) | -$13.09 M(+10.8%) |
| Sept 2016 | - | -$861.00 K(-73.5%) | -$11.81 M(-32.8%) |
| June 2016 | - | -$3.25 M(-48.2%) | -$17.57 M(-23.5%) |
| Mar 2016 | - | -$6.27 M(+338.2%) | -$22.96 M(-0.1%) |
| Dec 2015 | -$22.98 M(+23.6%) | -$1.43 M(-78.4%) | -$22.98 M(-25.3%) |
| Sept 2015 | - | -$6.62 M(-23.3%) | -$30.75 M(+8.8%) |
| June 2015 | - | -$8.63 M(+37.2%) | -$28.27 M(+16.1%) |
| Mar 2015 | - | -$6.29 M(-31.6%) | -$24.34 M(+30.9%) |
| Dec 2014 | -$18.59 M(+18.9%) | -$9.20 M(+121.9%) | -$18.59 M(+110.3%) |
| Sept 2014 | - | -$4.14 M(-11.9%) | -$8.84 M(-0.7%) |
| June 2014 | - | -$4.71 M(+760.1%) | -$8.91 M(-5.0%) |
| Mar 2014 | - | -$547.00 K(-198.9%) | -$9.38 M(-40.0%) |
| Dec 2013 | -$15.64 M(+5.5%) | $553.00 K(-113.1%) | -$15.64 M(-19.1%) |
| Sept 2013 | - | -$4.21 M(-18.6%) | -$19.34 M(+7.3%) |
| June 2013 | - | -$5.17 M(-24.0%) | -$18.03 M(+9.6%) |
| Mar 2013 | - | -$6.81 M(+116.3%) | -$16.45 M(+11.0%) |
| Dec 2012 | -$14.82 M(+48.4%) | -$3.15 M(+8.5%) | -$14.82 M(+4.7%) |
| Sept 2012 | - | -$2.90 M(-19.2%) | -$14.16 M(+0.6%) |
| June 2012 | - | -$3.59 M(-30.7%) | -$14.07 M(+10.6%) |
| Mar 2012 | - | -$5.18 M(+108.1%) | -$12.72 M(+27.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$9.98 M(+36.3%) | -$2.49 M(-11.5%) | -$9.98 M(+4.8%) |
| Sept 2011 | - | -$2.81 M(+25.4%) | -$9.53 M(+5.3%) |
| June 2011 | - | -$2.24 M(-8.2%) | -$9.05 M(+6.7%) |
| Mar 2011 | - | -$2.44 M(+20.1%) | -$8.48 M(+15.7%) |
| Dec 2010 | -$7.33 M(+117.4%) | -$2.03 M(-12.8%) | -$7.33 M(+4.1%) |
| Sept 2010 | - | -$2.33 M(+39.3%) | -$7.04 M(+17.7%) |
| June 2010 | - | -$1.67 M(+29.6%) | -$5.98 M(+11.2%) |
| Mar 2010 | - | -$1.29 M(-26.1%) | -$5.38 M(+59.7%) |
| Dec 2009 | -$3.37 M(+22.9%) | -$1.74 M(+37.1%) | -$3.37 M(-528.3%) |
| Sept 2009 | - | -$1.27 M(+18.7%) | $786.60 K(+579.3%) |
| June 2009 | - | -$1.07 M(-248.8%) | $115.80 K(-113.2%) |
| Mar 2009 | - | $720.10 K(-70.1%) | -$878.20 K(-68.0%) |
| Dec 2008 | -$2.74 M(-59.0%) | $2.41 M(-224.1%) | -$2.74 M(-50.4%) |
| Sept 2008 | - | -$1.94 M(-5.9%) | -$5.53 M(-11.5%) |
| June 2008 | - | -$2.07 M(+80.7%) | -$6.25 M(-0.7%) |
| Mar 2008 | - | -$1.14 M(+205.6%) | -$6.29 M(-5.9%) |
| Dec 2007 | -$6.69 M(-0.8%) | -$374.10 K(-86.0%) | -$6.69 M(-14.1%) |
| Sept 2007 | - | -$2.66 M(+26.1%) | -$7.79 M(+32.7%) |
| June 2007 | - | -$2.11 M(+37.2%) | -$5.87 M(+6.9%) |
| Mar 2007 | - | -$1.54 M(+4.4%) | -$5.49 M(-18.6%) |
| Dec 2006 | -$6.74 M(-32.5%) | -$1.47 M(+98.0%) | -$6.74 M(-20.1%) |
| Sept 2006 | - | -$744.70 K(-57.0%) | -$8.44 M(+20.0%) |
| June 2006 | - | -$1.73 M(-38.0%) | -$7.03 M(-20.2%) |
| Mar 2006 | - | -$2.79 M(-11.8%) | -$8.81 M(-11.9%) |
| Dec 2005 | -$10.00 M(-35.0%) | -$3.17 M(-580.3%) | -$10.00 M(-3.1%) |
| Sept 2005 | - | $659.20 K(-118.8%) | -$10.32 M(-34.3%) |
| June 2005 | - | -$3.51 M(-11.8%) | -$15.70 M(+3.3%) |
| Mar 2005 | - | -$3.98 M(+14.1%) | -$15.20 M(-1.2%) |
| Dec 2004 | -$15.37 M(-3.8%) | -$3.49 M(-26.2%) | -$15.37 M(-3.1%) |
| Sept 2004 | - | -$4.72 M(+57.1%) | -$15.86 M(+10.7%) |
| June 2004 | - | -$3.01 M(-27.7%) | -$14.33 M(-15.3%) |
| Mar 2004 | - | -$4.16 M(+4.6%) | -$16.92 M(+5.9%) |
| Dec 2003 | -$15.99 M(-42.8%) | -$3.97 M(+24.5%) | -$15.99 M(-7.1%) |
| Sept 2003 | - | -$3.19 M(-43.0%) | -$17.22 M(-20.2%) |
| June 2003 | - | -$5.60 M(+74.1%) | -$21.58 M(-8.2%) |
| Mar 2003 | - | -$3.22 M(-38.1%) | -$23.52 M(-15.8%) |
| Dec 2002 | -$27.93 M(+55.6%) | -$5.20 M(-31.1%) | -$27.93 M(-3.2%) |
| Sept 2002 | - | -$7.56 M(+0.3%) | -$28.85 M(+17.8%) |
| June 2002 | - | -$7.54 M(-1.2%) | -$24.50 M(+15.9%) |
| Mar 2002 | - | -$7.63 M(+24.6%) | -$21.14 M(+17.7%) |
| Dec 2001 | -$17.96 M(+86.4%) | -$6.12 M(+91.1%) | -$17.96 M(+8.2%) |
| Sept 2001 | - | -$3.21 M(-23.2%) | -$16.60 M(+6.5%) |
| June 2001 | - | -$4.18 M(-6.2%) | -$15.59 M(+7.9%) |
| Mar 2001 | - | -$4.45 M(-6.6%) | -$14.45 M(+50.0%) |
| Dec 2000 | -$9.63 M(+104.9%) | -$4.76 M(+116.7%) | -$9.63 M(+97.9%) |
| Sept 2000 | - | -$2.20 M(-27.6%) | -$4.87 M(+82.4%) |
| June 2000 | - | -$3.04 M(-927.0%) | -$2.67 M(-827.0%) |
| Mar 2000 | - | $367.10 K | $367.10 K |
| Dec 1999 | -$4.70 M(-17.1%) | - | - |
| Dec 1998 | -$5.67 M(+77.5%) | - | - |
| Dec 1997 | -$3.20 M | - | - |
FAQ
- What is Seelos Therapeutics annual free cash flow?
- What is the all time high annual FCF for Seelos Therapeutics?
- What is Seelos Therapeutics annual FCF year-on-year change?
- What is Seelos Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Seelos Therapeutics?
- What is Seelos Therapeutics quarterly FCF year-on-year change?
- What is Seelos Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Seelos Therapeutics?
- What is Seelos Therapeutics TTM FCF year-on-year change?
What is Seelos Therapeutics annual free cash flow?
The current annual FCF of SEEL is -$23.91 M
What is the all time high annual FCF for Seelos Therapeutics?
Seelos Therapeutics all-time high annual free cash flow is -$2.74 M
What is Seelos Therapeutics annual FCF year-on-year change?
Over the past year, SEEL annual free cash flow has changed by +$37.69 M (+61.18%)
What is Seelos Therapeutics quarterly free cash flow?
The current quarterly FCF of SEEL is -$972.00 K
What is the all time high quarterly FCF for Seelos Therapeutics?
Seelos Therapeutics all-time high quarterly free cash flow is $2.68 M
What is Seelos Therapeutics quarterly FCF year-on-year change?
Over the past year, SEEL quarterly free cash flow has changed by +$4.78 M (+83.09%)
What is Seelos Therapeutics TTM free cash flow?
The current TTM FCF of SEEL is -$13.27 M
What is the all time high TTM FCF for Seelos Therapeutics?
Seelos Therapeutics all-time high TTM free cash flow is $786.60 K
What is Seelos Therapeutics TTM FCF year-on-year change?
Over the past year, SEEL TTM free cash flow has changed by +$21.82 M (+62.17%)